Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria

• Olanrewaju Oladimeji ,

  * E-mail: droladfb@gmail.com

  Affiliations Zankli Medical Centre, Abuja, Nigeria, Liverpool School of Tropical Medicines, Pembroke Place, Liverpool, United Kingdom

  ⨯
• Petros Isaakidis,

  Affiliation Médecins Sans Frontières (MSF), Operational Research Unit, Luxemburg, Luxemburg

  ⨯
• Olusegun J. Obasanya,

  Affiliation National Tuberculosis and Leprosy Control Unit, Federal Ministry of Health, Abuja, Nigeria

  ⨯
• Osman Eltayeb,

  Affiliation Damien Foundation Belgium, Nigeria Project, Ibadan, Nigeria

  ⨯
• Mohammed Khogali,

  Affiliation Médecins Sans Frontières (MSF), Operational Research Unit, Luxemburg, Luxemburg

  ⨯
• Rafael Van den Bergh,

  Affiliation Médecins Sans Frontières (MSF), Operational Research Unit, Luxemburg, Luxemburg

  ⨯
• Ajay M. V. Kumar,

  Affiliation International Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Regional Office, New Delhi, India

  ⨯
• Sven Gudmund Hinderaker,

  Affiliation Centre for International Health, University of Bergen, Bergen, Norway

  ⨯
• Saddiq T. Abdurrahman,

  Affiliation Tuberculosis and Leprosy Control Program, Federal Capital Territory, Abuja, Nigeria

  ⨯
• Lovett Lawson,

  Affiliation Zankli Medical Centre, Abuja, Nigeria

  ⨯
• Luis E. Cuevas

  Affiliation Liverpool School of Tropical Medicines, Pembroke Place, Liverpool, United Kingdom

  ⨯